nach oben

Erschienen in:

01.02.2015 | Research Article

Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer

verfasst von: F. Arias, V. Chicata, M. J. García-Velloso, G. Asín, M. Uzcanga, C. Eito, I. Quilez, A. Viudez, J. Saenz, I. Hernández, C. Caicedo, M. Errasti, M. Barrado, F. García-Bragado

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the impact of initial FDG PET/CT staging on clinical stage and the management plan in patients with locally advanced head and neck cancer (LAHNC).

Materials and methods

We retrospectively reviewed the records of 72 consecutive patients (2007–2010) staged with PET/CT and conventional CT with tumours of hypopharynx/larynx (26 patients, 36 %), oral cavity (17 patients, 24 %), oropharynx (16 patients, 22 %), nasopharynx (12 patients, 17 %), and others (2 %). The impact of PET/CT on management plans was considered high when PET/CT changed the planned treatment modality or treatment intent, and intramodality changes were considered as minor changes with low impact.

Results

FDG PET/CT changed the stage in 27 patients and had high impact on the management plan in 12 % of patients (detection of distant metastases in 6 patients and stage II in 2 patients). Intramodality changes were more frequent: FDG PET/CT altered the TNM stage in 18/72 (25 %) of patients, upstaging N stage in 90 % of patients with low impact.

Conclusions

Initial FDG PET/CT staging not only improves stage but also affects the management plan in LAHNC patients.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef

Carvalho AL, Nishimoto IN, Califano JA, Kowalsky LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–16.PubMedCrossRef

Porceddu SV, Burmeister BH, Hicks RJ. Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond. Hematol Oncol Clin North Am. 2008;22:1221–38.PubMedCrossRef

Schöder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180–97.PubMedCrossRef

Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1593–600.PubMedCrossRef

Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991–9.PubMedCrossRef

Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck. 2005;27:175–81.PubMedCrossRef

Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645–50.PubMedCrossRef

Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–208.PubMedCrossRef

10.

Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315–22.PubMedCrossRef

11.

American joint committee on cancer—cancer staging manual. 7th ed. New York: Springer; 2010.

12.

Kolarova I, Vanasek J, Kandrnal V, Odrazka K, Dusek L, Chrobok V, et al. PET/CT significance for planning radiotherapy of head and neck cancer. Neoplasma. 2012;59(5):536–40.PubMedCrossRef

13.

Newbold K, Powell C. PET/CT in radiotherapy planning for head and neck cancer. Front Oncol. 2012;2:article 189.CrossRef

14.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), version 1; 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

15.

Suzuki M, Suzuki T, Asai M, Ichimura K, Nibu K, Sugasawa M, et al. Clinicopathologic factors related to cervical lymph node metastasis in a patient with carcinoma of the oral floor. Acta Oto Laryngol. 2007;127:129–35.CrossRef

16.

Wallwork BD, Anderson SR, Coman WB. Squamous cell carcinoma of the floor of the mouth: tumor thickness and the rate of cervical metastasis. ANZ J Surg. 2007;77:761–4.PubMedCrossRef

17.

Sessions DG, Spector GJ, Lenox J, Chao C, Chaudry OA. Analysis of treatment results for oral tongue cancer. Laryngoscope. 2002;112:616–25.PubMedCrossRef

18.

Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med. 2008;38:141–8.PubMedCrossRef

19.

Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis LW. F-18 FDG PET–CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck. 2005;27(6):494–502.PubMedCrossRef

20.

Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL Jr, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(5):906–14.

21.

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37(4):691–8.

Titel: Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer
verfasst von: F. Arias
V. Chicata
M. J. García-Velloso
G. Asín
M. Uzcanga
C. Eito
I. Quilez
A. Viudez
J. Saenz
I. Hernández
C. Caicedo
M. Errasti
M. Barrado
F. García-Bragado
Publikationsdatum: 01.02.2015
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 2/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1204-8

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer

Abstract

Objective

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Objective

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis

Genetic modification of hypoxia signaling in animal models and its effect on cancer

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment

Change of the editorial board

Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie